Nutanix Boosts Revenue Forecast for Fiscal Year 2025 to $2.53 Billion

Published 10 hours agoNTNX

Nutanix Boosts Revenue Forecast for Fiscal Year 2025 to $2.53 Billion

Nutanix has recently announced an increase in its fiscal year 2025 revenue guidance, now projecting $2.53 billion, according to Benzinga. This upward revision reflects strong growth in new customer acquisitions and expanded partnerships, signaling confidence in the company's strategy and market trajectory.

The company also reported a noteworthy 16% year-over-year revenue increase for the second quarter of fiscal 2025, reaching $654.7 million and exceeding analyst expectations. Further highlighting its strong performance, Nutanix achieved a 19% year-over-year growth in annual recurring revenue. This boost is attributed to a growing demand for its subscription-based services, as reported by Benzinga.

Moreover, Nutanix has strengthened its partnership with Amazon Web Services (AWS) to enhance service offerings for customers migrating to Nutanix Cloud Clusters (NC2) on AWS, as noted by GlobeNewswire. Analysts have responded positively, with Raymond James raising the company's stock target price to $83 based on these favorable outcomes and promising financial guidance. Nutanix's strategic moves and solid financial results showcase its resilient market position.

Share this article

Twitter Facebook LinkedIn

Recent Articles

E.l.f. Beauty Acquires Hailey Bieber's Rhode for Up to $1 Billion

E.l.f. Beauty Acquires Hailey Bieber's Rhode for Up to $1 Billion

15 minutes agoELF

E.l.f. Beauty is making waves with its latest acquisition of Hailey Bieber's skincare line, Rhode, in a deal that could reach up to $1 billion. The agreement includes $600 million in cash, $200 million in newly issued E.l.f. common stock, and a potential earnout of $200 million, dependent on Rhode's performance over the next three years, according to the Associated Press. Rhode has demonstrated significant market potential with $212 million in net sales reported for the fiscal year ending March 31, 2025. The brand currently operates primarily through online sales but is planning a significant retail expansion. By the end of the year, Rhode is set to enter the physical retail space with a partnership with Sephora in North America and the U.K., as reported by Reuters. Keeping its creative force intact, Hailey Bieber will continue to play a vital role as Chief Creative Officer and Head of Innovation at Rhode, focusing on creative direction, product development, and marketing. She will also lend her insight as a strategic advisor to both E.l.f. and Rhode. Investor reactions were positive, with E.l.f.'s stock climbing 12% in premarket trading following the acquisition news.

Alzamend Neuro Begins Phase II Trial for New Bipolar Disorder Treatment

Alzamend Neuro Begins Phase II Trial for New Bipolar Disorder Treatment

30 minutes agoALZN

Alzamend Neuro has announced that it will initiate a Phase II clinical trial for AL001, its novel lithium delivery system, aimed at treating bipolar disorder (BD). The trial is set to commence in the third quarter of 2025, marking a significant step in the development of advanced treatment options for BD patients. The trial, to be conducted at Massachusetts General Hospital, will pit AL001 against a marketed lithium carbonate product. The objective is to compare lithium blood levels and brain pharmacokinetics in patients. Preclinical studies have shown promising results, suggesting that AL001 enhances brain absorption while maintaining lower blood lithium levels, potentially reducing systemic side effects. Alzamend Neuro CEO Stephan Jackman has highlighted the potential of AL001 to transform BD care by improving safety and brain targeting without the need for therapeutic drug monitoring. The company aims to provide a more user-friendly and effective treatment path, facilitating better patient outcomes and quality of life.

Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Application

Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Application

45 minutes agoMRK

Merck and Daiichi Sankyo have decided to pull their U.S. application for the experimental lung cancer drug known as patritumab deruxtecan. This decision comes after the drug failed to show a survival benefit in a late-stage clinical trial, as reported by Reuters. The drug was aimed at treating patients with non-small cell lung cancer who had exhausted at least two other treatment options and possessed a particular gene mutation linked to abnormal cell growth. The drug, designed as a targeted therapy to attack cancer cells while sparing healthy ones, was expected to provide a new option for hard-to-treat cancer cases. However, the trial results did not meet expectations in demonstrating a clear survival advantage. This follows a previous setback when the U.S. Food and Drug Administration declined to approve the therapy due to manufacturing issues at a third-party facility. The withdrawal of the application is likely to have implications for Merck and Daiichi Sankyo's efforts in developing innovative cancer treatments. Both companies have been working together to advance targeted therapy options, and this development may impact their collaborative oncology pipeline and strategies.

Kohl's Posts Smaller Q1 Loss, Sticks to Full-Year Forecast

Kohl's Posts Smaller Q1 Loss, Sticks to Full-Year Forecast

Kohl's Corporation surpassed analyst expectations with its first-quarter 2025 earnings report, announcing a smaller than anticipated loss. The company reported a loss of $0.13 per share, improving over its earlier estimate of a $0.20 to $0.24 loss and beating analysts' forecast of a $0.26 loss, Reuters reported. Even though comparable sales declined by 3.9%, this was slightly less severe than the predicted 4% to 4.3% drop. Kohl's is also maintaining its full-year sales outlook with projections of a 5% to 7% decline and anticipates annual earnings per share to range between $0.10 and $0.60. In response to the latest earnings news, Kohl's shares rose by 6% in premarket trading. Kohl's is committed to strategic changes, focusing on closing underperforming locations and bolstering its collaboration with Sephora. The retailer plans to expand its Sephora presence to over 1,100 mini-stores within Kohl's by the end of the year. These steps demonstrate the retailer's ongoing efforts to adapt and strengthen its market position.